Literature DB >> 31625031

Association of lifestyle and clinical characteristics with receipt of radiotherapy treatment among women diagnosed with DCIS in the NIH-AARP Diet and Health Study.

Maeve Mullooly1, Diana R Withrow2, Rochelle E Curtis2, Shaoqi Fan2, Linda M Liao2, Ruth M Pfeiffer2, Amy Berrington de González2, Gretchen L Gierach2.   

Abstract

PURPOSE: The long-term risks and benefits of radiotherapy for ductal carcinoma in situ (DCIS) remain unclear. Recent data from the Surveillance, Epidemiology and End Results (SEER) registries showed that DCIS-associated radiotherapy treatment significantly increased risk of second non-breast cancers including lung cancer. To help understand those observations and whether breast cancer risk factors are related to radiotherapy treatment decision-making, we examined associations between lifestyle and clinical factors with DCIS radiotherapy receipt.
METHODS: Among 1628 participants from the NIH-AARP Diet and Health Study, diagnosed with incident DCIS (1995-2011), we examined associations between lifestyle and clinical factors with radiotherapy receipt. Radiotherapy and clinical information were ascertained from state cancer registries. Odds ratios (ORs) and 95% confidence intervals (CIs) for radiotherapy receipt (yes/no) were estimated from multivariable logistic regression.
RESULTS: Overall, 45% (n = 730) received radiotherapy. No relationships were observed for most lifestyle factors and radiotherapy receipt, including current smoking (OR 0.97, 95%CI 0.70, 1.34). However positive associations were observed for moderate alcohol consumption and infrequent physical activity. The strongest associations were observed for radiotherapy receipt and more recent diagnoses (2005-2011 vs. 1995-1999; OR 1.60, 95%CI 1.14, 2.25), poorly versus well-differentiated tumors (OR 1.69, 95%CI 1.16, 2.46) and endocrine therapy (OR 3.37, 95%CI 2.56, 4.44).
CONCLUSIONS: Clinical characteristics were the strongest determinants of DCIS radiotherapy. Receipt was largely unrelated to lifestyle factors suggesting that the previously observed associations in SEER were likely not confounded by these lifestyle factors. Further studies are needed to understand mechanisms driving radiotherapy-associated second malignancies following DCIS, to identify prevention opportunities for this growing population.

Entities:  

Keywords:  AARP; DCIS; Radiotherapy; Risk factors; Second cancers

Mesh:

Year:  2019        PMID: 31625031      PMCID: PMC8237617          DOI: 10.1007/s10549-019-05436-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  25 in total

1.  The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS score™ result.

Authors:  Michael Alvarado; Dennis L Carter; J Michael Guenther; James Hagans; Rachel Y Lei; Charles E Leonard; Jennifer Manders; Amy P Sing; Michael S Broder; Dasha Cherepanov; Eunice Chang; Marianne Eagan; Wendy Hsiao; Michael J Schultz
Journal:  J Surg Oncol       Date:  2015-05-28       Impact factor: 3.454

2.  Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions.

Authors:  Chieh-Yu Lin; Kelly Mooney; Winward Choy; Soo-Ryum Yang; Keegan Barry-Holson; Kathleen Horst; Irene Wapnir; Kimberly Allison
Journal:  Mod Pathol       Date:  2017-12-15       Impact factor: 7.842

3.  Radiotherapy for ductal carcinoma in situ and risk of second non-breast cancers.

Authors:  Diana R Withrow; Lindsay M Morton; Rochelle E Curtis; Sara J Schonfeld; Amy Berrington de González
Journal:  Breast Cancer Res Treat       Date:  2017-07-25       Impact factor: 4.872

Review 4.  Epidemiology of ductal carcinoma in situ.

Authors:  Karla Kerlikowske
Journal:  J Natl Cancer Inst Monogr       Date:  2010

5.  Trends in the treatment of ductal carcinoma in situ of the breast.

Authors:  Nancy N Baxter; Beth A Virnig; Sara B Durham; Todd M Tuttle
Journal:  J Natl Cancer Inst       Date:  2004-03-17       Impact factor: 13.506

Review 6.  Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.

Authors:  C Correa; P McGale; C Taylor; Y Wang; M Clarke; C Davies; R Peto; N Bijker; L Solin; S Darby
Journal:  J Natl Cancer Inst Monogr       Date:  2010

7.  Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ.

Authors:  Dean A Shumway; Chandler M McLeod; Monica Morrow; Yun Li; Allison W Kurian; Aaron Sabolch; Ann S Hamilton; Kevin C Ward; Steven J Katz; Sarah T Hawley; Reshma Jagsi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-01-09       Impact factor: 8.013

Review 8.  Medical factors influencing decision making regarding radiation therapy for breast cancer.

Authors:  Christina A Dilaveri; Nicole P Sandhu; Lonzetta Neal; Michelle A Neben-Wittich; Tina J Hieken; Maire Brid Mac Bride; Dietlind L Wahner-Roedler; Karthik Ghosh
Journal:  Int J Womens Health       Date:  2014-11-19

9.  A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone.

Authors:  Eileen Rakovitch; Sharon Nofech-Mozes; Wedad Hanna; Frederick L Baehner; Refik Saskin; Steven M Butler; Alan Tuck; Sandip Sengupta; Leela Elavathil; Prashant A Jani; Michel Bonin; Martin C Chang; Susan J Robertson; Elzbieta Slodkowska; Cindy Fong; Joseph M Anderson; Farid Jamshidian; Dave P Miller; Diana B Cherbavaz; Steven Shak; Lawrence Paszat
Journal:  Breast Cancer Res Treat       Date:  2015-06-29       Impact factor: 4.872

10.  A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.

Authors:  Lawrence J Solin; Robert Gray; Frederick L Baehner; Steven M Butler; Lorie L Hughes; Carl Yoshizawa; Diana B Cherbavaz; Steven Shak; David L Page; George W Sledge; Nancy E Davidson; James N Ingle; Edith A Perez; William C Wood; Joseph A Sparano; Sunil Badve
Journal:  J Natl Cancer Inst       Date:  2013-05-02       Impact factor: 13.506

View more
  1 in total

1.  Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation.

Authors:  Kang Wang; Zhuyue Li; Xingxing Chen; Jianjun Zhang; Yongfu Xiong; Guochao Zhong; Yang Shi; Qing Li; Xiang Zhang; Hongyuan Li; Tingxiu Xiang; Theodoros Foukakis; Tomas Radivoyevitch; Guosheng Ren
Journal:  NPJ Breast Cancer       Date:  2021-03-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.